We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genflow Biosciences Plc | GENF | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.15 | 7.32% | 2.20 | 13:13:56 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.05 | 2.05 | 2.20 | 2.20 | 2.05 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 26/6/2024 14:58 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,651 followers 2h A recent survey reveals that many Americans prefer a shorter, healthier life over a longer one burdened by diseases that impact their quality of life. But what if modern medicine could offer both longevity and health? Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s dedicated team of experienced researchers is at the forefront of the medical industry, working tirelessly to turn this possibility into a reality. We are committed to developing solutions that promise a longer and healthier life for everyone. Read more here: #GENF #aging #healthspan #longevity |
Posted at 18/6/2024 19:07 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,643 followers 6h While advanced anti-aging treatments are on the horizon, The Economist has researched ways humans can extend their #healthspan presently. Italian scientist Valter Longo has sworn by fasting for years after learning about its benefits during his time at the USC Longevity Institute. While lifestyle choices significantly impact #longevity, emerging treatments also promise enhanced and extended quality of life. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) works with the #centenarian variant of the #SIRT6 gene, which has been correlated with a longer lifespan. This groundbreaking work has the potential to revolutionize how we treat a number of aging related diseases. Read the article here: #longevity #aging #GENF |
Posted at 11/6/2024 13:28 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,633 followers 56m A recent Prevention article pointed to daily exercise and a diet high in fruits & vegetables as ways to increase your #lifespan. These measures do offer moderate improvements, yet #biotech research promises a much more significant extension. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) promising #SIRT6 research is an example of research conducted that could combat aging and its symptoms. Coupled with our growing IP portfolio, it’s no wonder The Guardian named us a firm to watch in 2024! Read the Prevention article to learn how to extend your #healthspan in the meantime: #aging #healthspan #GENF |
Posted at 16/5/2024 15:37 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,606 followers 3h The #biotech space has continued to out perform expectations. As the industry is teetering on another market rally, many companies have had exciting developments. Regeneron, for one, has announced it successfully restored the hearing of two children experiencing otoferlin hearing loss. Additionally, Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has secured several significant grants, some of whose payment is expected imminently. These will help advance its #sarcopenia & #mRNA delivery research. Learn about Genflow's exciting investment proposition: #pharma #aging #GENF |
Posted at 14/5/2024 20:38 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,604 followers 8h The #biotech space is cluttered with many companies claiming to be on the cutting edge, with little to back this up. Genflow Biosciences (LON:GENF) (OTCQB:GENFF), on the other hand, stands out in numerous ways. Differentiating between the true innovators and the rest can be difficult. That's why we've created a new fact sheet summarizing our exciting research that aims to extend both human and canine #healthspan. What sets #GENF apart: ✅ Long life IP, protecting our #SIRT6 cenenarian gene & gene delivery research ✅ Creating #NASH treatment to address untapped market of 35 million people ✅ Lead by experienced team with a background running public companies Learn more about Genflow's exciting investment thesis: |
Posted at 01/5/2024 19:19 by moneymunch Interesting for Genflow to post the following on Linkedin a couple of hours after suspension. Gla -)Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,594 followers 6h Stay up-to-date with Genflow Biosciences (LON:GENF) (OTCQB:GENFF)! Sign up for our latest updates and be the first to know about our groundbreaking advancements. Don't miss important news & exclusive insights - subscribe now: #GENF #GENFF #biotech #genetherapy #aging |
Posted at 25/4/2024 12:54 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,585 followers 23m 🧬 Genflow Biosciences has an updated presentation! 🧬 To learn more about the cutting-edge #biotech research & studies currently underway, as well as Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s strong investment thesis, click here: #SIRT6 #GENF #NASH #aging #healthspan |
Posted at 24/4/2024 06:47 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,585 followers 18h Safety paramount in the #biotech industry, and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF), it's our top priority. We're proud to have developed patent-pending technology to enhance safety in our #SIRT6 studies. It is this unwavering commitment to safety that has allowed us to advance a number of our studies to the pre-clinical/develop Learn more about Genflow's innovative studies & exciting investment thesis: #GENF #aging #healthspan #NASH #genetherapy Investors – Genflow Bioscience |
Posted at 27/1/2024 08:49 by moneymunch UpdatesView organization page for Genflow Biosciences (LON:GENF) (OTCQB:GENFF) Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,455 followers 20h Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is excited to announce the release of its Annual 2023 Year in Review. This past year, we have achieved significant progress in our primary research areas in Non-Alcoholic Steatohepatitis (NASH) and Werner Syndrome. Alongside these achievements, we have also made considerable strides in fortifying our corporate structure, enhancing our financial stability, and expanding our market presence to North America. Read it here: #longevity #NASH #Werner #SIRT6 #ageing #Genflow #GENF |
Posted at 13/6/2023 07:02 by moneymunch RNS Number : 4646CGenflow Biosciences PLC 13 June 2023 Genflow Biosciences Plc ("Genflow" or "the Company") Anti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture Market in addition to its LSE Main Market Listing Genflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner Syndrome Genflow Biosciences Plc ("Genflow" or "the Company") is pleased to announce that, after a successful application process, its Ordinary Shares ("Ordinary Shares") begin trading on the OTCQB Venture Market in the United States ("US") today under the symbol GENFF. Genflow will continue to trade on the London Stock Exchange ("LSE") Main Market under the symbol GENF, and, importantly, the onboarding to this additional U.S. securities trading platform does not involve any capital raise. The new U.S. trading facility expands access to a broader pool of investors and enables investors in the United States to trade during U.S. trading hours and in U.S. dollars. Eric Leire, CEO of Genflow, expressed his excitement about this significant achievement, stating, "We are thrilled to announce that Genflow Biosciences has been admitted to trading on the OTCQB Venture Market in the United States. This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange." Tamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of the Board of Directors, saying, "Genflow is developing gene therapies that could address an important source of many global illnesses: aging. As the Company moves into Phase I/II clinical trials to treat potentially the orphan condition Werner Syndrome, which causes premature aging, and NASH, a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors." Further information on Genflow's application and the OTCQB market is below: As a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs; admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. Under this exemption, the Company must ensure that information made public or distributed under its home market regulations is made available to the public on its website or another electronic information delivery system in English. Consequently, Genflow will have no additional reporting obligations and will incur minimal ongoing costs compared to traditional major exchanges. As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker-dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments on a BSF page on the OTC Markets website at www.otcmarkets.com. Genflow appointed the corporate securities law firm Galanopoulos & Company as its OTCQB Sponsor to support its onboarding to the OTCQB Venture Market. Additional information about the OTCQB market can be found at: www.otcmarkets.com/l The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
